Research& Development

Learn more

INNOVATION, A PRIORITY

10%
10% of VIVACY’s revenue is invested in research every year.
10
10 years of engagement in research and innovations.
1st
1st priority is quality and safety of the products.
x11
x11 the production capacity in 8 years.
2
2 Patented Technologies: IPN-Like, Bi-SOFT®*.
6M
6 million treatments done in the world**.

INNOVATION, A PRIORITY

All VIVACY’s injectable products are designed and developed in the VIVACY’s Research & Development Laboratory, which is entirely dedicated to innovation in the Anti-Ageing and Aesthetics fields.

The Laboratoires VIVACY is always seeking to develop innovative, safe and high-quality injectable products meeting patients’ and doctors’ expectations and needs, in compliance with the European and International medical device regulations.

The R&D, Production, Quality & Regulatory Affairs’ teams work together towards a common goal of making high-end, well tolerated and safe injectable products for the patients.

* IPN-Like Technology Patent delivered WO2009/071697 in 2008 and Bi-SOFT® Technology Patent submitted FR3064489 A1 in 2017.
** 7 millions of syringes sold in the world between 2008 and 31/08/18.

By continuing to browse this website, you agree to the use of cookies or other tracking devices to track visits.
For more information and to configure the tracking devices.
I agreeMore info
When you browse our website, information may be saved, or read, in your computer, according to your choices. Do you agree that cookies are used and read in order to analyse your navigation and to allow us to measure the audience of our website?